Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- PMID: 37036398
- DOI: 10.1093/bjd/ljad118
Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
Erratum in
-
Correction to: Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib.Br J Dermatol. 2024 Jan 23;190(2):e12. doi: 10.1093/bjd/ljad368. Br J Dermatol. 2024. PMID: 37774370 No abstract available.
Conflict of interest statement
Conflicts of interest R.D.S. is an Associate Editor of the AJD; reports being a Director and Founder of Samson Clinical Pty Ltd; participates on the pharmaceutical advisory board for Eli Lilly, Pfizer Inc. and Leo Pharmaceutical; is on the speakers bureau for AbbVie and Novartis; and is a Principal Investigator (PI) in clinical trials for Amgen, Novartis, Arcutis Biotherapeutics, Aerotech, Merck and Co., Celgene, Coherus BioSciences, Jannsen, Regeneron, MedImmune, GlaxoSmithKline, Samson Clinical, Boehringer Ingelheim, Oncobiologics, Roche, Ascend, Dermira, AstraZeneca, Akesobio, Reistone Biopharma, UCB, Sanofi, Connect, Arena, Sun Pharma, Bristol Myer Squibb and Galderma. S.E. reports being a member of the dermatology advisory board for Eli Lilly and PI in clinical trials for Pfizer Inc., AbbVie, Arena Pharmaceuticals, Boston Pharmaceuticals, Bristol-Myers Squibb, Botanix, Dermira, Eli Lilly, LEO Pharma, Novartis, Regeneron, Tigermed, Suzhou Connect Biopharmaceuticals, Janssen, Kymab Ltd, KoBiolabs and Avance Clinical. L.A., A.M., B.B., L.B. and H.R. declare no conflicts of interest.
Similar articles
-
Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients.J Am Acad Dermatol. 2024 May;90(5):1059-1061. doi: 10.1016/j.jaad.2023.09.089. Epub 2024 Jan 20. J Am Acad Dermatol. 2024. PMID: 38246562 No abstract available.
-
Baricitinib (Olumiant) for the Treatment of Alopecia Areata.Am Fam Physician. 2023 Nov;108(5):513-514. Am Fam Physician. 2023. PMID: 37983706 No abstract available.
-
Alopecia areata treatment with baricitinib: different relapse phenotypes.J Dermatolog Treat. 2024 Dec;35(1):2324832. doi: 10.1080/09546634.2024.2324832. Epub 2024 Mar 11. J Dermatolog Treat. 2024. PMID: 38465657 No abstract available.
-
Baricitinib: A Review in Severe Alopecia Areata.Am J Clin Dermatol. 2023 Jul;24(4):661-668. doi: 10.1007/s40257-023-00799-z. Epub 2023 Jun 16. Am J Clin Dermatol. 2023. PMID: 37326792 Review.
-
Review of Baricitinib in the Treatment of Alopecia Areata.J Drugs Dermatol. 2023 Sep 1;22(9):935-940. doi: 10.36849/JDD.7357. J Drugs Dermatol. 2023. PMID: 37683061 Review.
Cited by
-
Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up.J Asthma Allergy. 2024 Apr 2;17:305-311. doi: 10.2147/JAA.S458684. eCollection 2024. J Asthma Allergy. 2024. PMID: 38585501 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical